Ekso Bionics Holdings Toekomstige groei

Future criteriumcontroles 5/6

De verwachting is dat Ekso Bionics Holdings de winst en omzet met respectievelijk 73% en 23.8% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 74.5% per jaar.

Belangrijke informatie

73.0%

Groei van de winst

74.5%

Groei van de winst per aandeel

Medical Equipment winstgroei	17.1%
Inkomstengroei	23.8%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	29 Oct 2024

Recente toekomstige groei-updates

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.00

May 02

Recent updates

Take Care Before Jumping Onto Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Even Though It's 27% Cheaper

Nov 12

Investors Give Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Shares A 26% Hiding

Aug 29

Many Still Looking Away From Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)

Jul 13

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.00

May 02

Market Still Lacking Some Conviction On Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)

Dec 20

Winst- en omzetgroeiprognoses

NasdaqCM:EKSO - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	30	1	N/A	N/A	1
12/31/2025	25	-5	N/A	N/A	2
12/31/2024	18	-10	N/A	N/A	2
9/30/2024	18	-11	-10	-10	N/A
6/30/2024	18	-12	-11	-11	N/A
3/31/2024	18	-14	-11	-11	N/A
12/31/2023	18	-15	-12	-12	N/A
9/30/2023	17	-15	-14	-14	N/A
6/30/2023	16	-16	-14	-13	N/A
3/31/2023	14	-15	-15	-15	N/A
12/31/2022	13	-15	-15	-15	N/A
9/30/2022	13	-15	-14	-14	N/A
6/30/2022	13	-12	-14	-14	N/A
3/31/2022	12	-11	-13	-13	N/A
12/31/2021	11	-10	-11	-11	N/A
9/30/2021	9	-11	-10	-10	N/A
6/30/2021	9	-6	-9	-9	N/A
3/31/2021	9	-17	-9	-9	N/A
12/31/2020	9	-16	-9	-9	N/A
9/30/2020	10	-15	-9	-9	N/A
6/30/2020	11	-17	-12	-12	N/A
3/31/2020	12	-8	-12	-12	N/A
12/31/2019	14	-12	-16	-16	N/A
9/30/2019	13	-14	-20	-19	N/A
6/30/2019	13	-21	-19	-19	N/A
3/31/2019	12	-26	-21	-21	N/A
12/31/2018	11	-27	-22	-22	N/A
9/30/2018	10	-32	-23	-23	N/A
6/30/2018	10	-31	N/A	-27	N/A
3/31/2018	8	-29	N/A	-31	N/A
12/31/2017	7	-29	N/A	-31	N/A
9/30/2017	7	-26	N/A	-30	N/A
6/30/2017	7	-31	N/A	-28	N/A
3/31/2017	7	-35	N/A	-25	N/A
12/31/2016	14	-34	N/A	-25	N/A
9/30/2016	14	-38	N/A	-26	N/A
6/30/2016	15	-31	N/A	-24	N/A
3/31/2016	15	-27	N/A	-21	N/A
12/31/2015	9	-24	N/A	-18	N/A
9/30/2015	8	-35	N/A	-16	N/A
6/30/2015	7	-18	N/A	-15	N/A
3/31/2015	6	44	N/A	-13	N/A
12/31/2014	5	-34	N/A	-15	N/A
9/30/2014	5	-16	N/A	-15	N/A
6/30/2014	4	-30	N/A	-12	N/A
3/31/2014	4	-90	N/A	-12	N/A
12/31/2013	3	-12	N/A	-9	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er wordt voorspeld dat EKSO de komende 3 jaar winstgevend zal worden, wat wordt beschouwd als een snellere groei dan de spaarquote ( 2.6% ).

Winst versus markt: Er wordt verwacht dat EKSO de komende 3 jaar winstgevend zal worden. Dit wordt gezien als een groei die boven het gemiddelde van de markt ligt.

Hoge groeiwinsten: Er wordt verwacht dat EKSO binnen 3 jaar winstgevend zal worden.

Omzet versus markt: De omzet van EKSO ( 23.8% per jaar) zal naar verwachting sneller groeien dan de markt US ( 9% per jaar).

Hoge groei-inkomsten: De omzet van EKSO ( 23.8% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van EKSO naar verwachting over 3 jaar hoog zal zijn

Ekso Bionics Holdings Toekomstige groei

Future criteriumcontroles 5/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus revenue estimates decrease by 11%, EPS upgraded

Forecast to breakeven in 2026

Consensus EPS estimates upgraded to US$0.43 loss, revenue downgraded

Price target increased by 8.1% to US$10.00

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.00

Forecast to breakeven in 2026

Recent updates

Take Care Before Jumping Onto Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Even Though It's 27% Cheaper

Consensus revenue estimates decrease by 11%, EPS upgraded

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Ekso Bionics Holdings, Inc. to Report Q3, 2024 Results on Oct 28, 2024

New major risk - Shareholder dilution

Ekso Bionics Holdings, Inc. has completed a Composite Units Offering in the amount of $5.9971 million.

Ekso Bionics Holdings, Inc. has completed a Composite Units Offering in the amount of $6 million.

Investors Give Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Shares A 26% Hiding

New major risk - Financial position

Forecast to breakeven in 2026

Second quarter 2024 earnings: EPS in line with expectations, revenues disappoint

Ekso Bionics Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Ekso Bionics Holdings, Inc. to Report Q2, 2024 Results on Jul 29, 2024

Many Still Looking Away From Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)

Ekso Bionics Holdings, Inc. Appoints Deborah Lafer Scher to its Board of Directors

Consensus EPS estimates upgraded to US$0.43 loss, revenue downgraded

Price target increased by 8.1% to US$10.00

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.00

Forecast to breakeven in 2026

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Ekso Bionics Holdings, Inc., Annual General Meeting, Jun 06, 2024

Ekso Bionics Holdings, Inc. to Report Q1, 2024 Results on Apr 29, 2024

Consensus EPS estimates fall by 145%

Price target decreased by 7.5% to US$9.25

No longer forecast to breakeven

Full year 2023 earnings: EPS misses analyst expectations

Ekso Bionics Holdings, Inc. to Report Q4, 2023 Results on Mar 04, 2024

Consensus estimates of losses per share improve by 26%

Forecast to breakeven in 2026

Ekso Bionics Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $4.6 million.

Ekso Bionics Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $4.6 million.

Ekso Bionics Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $4.6 million.

Ekso Bionics Holdings, Inc. Launches GaitCoach Software for EksoNR

Ekso Bionics Holdings, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023

Market Still Lacking Some Conviction On Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)

Ekso Bionics Holdings, Inc. Receives CMS Coding Approval for Ekso Indego Personal

New major risk - Share price stability

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Ekso Bionics Holdings, Inc. to Report Q3, 2023 Results on Oct 26, 2023

Ekso Bionics Holdings, Inc. Receives Non-Compliance Notice from Nasdaq

Consensus revenue estimates increase by 12%, EPS downgraded

New major risk - Financial position

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Ekso Bionics Holdings, Inc. to Report Q2, 2023 Results on Jul 27, 2023

New minor risk - Share price stability

Sentiment Still Eluding Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)

Executive Chairman of the Board recently sold US$66k worth of stock

Consensus EPS estimates fall by 40%

High number of new and inexperienced directors

No longer forecast to breakeven

Full year 2022 earnings released: US$1.16 loss per share (vs US$0.80 loss in FY 2021)

Forecast to breakeven in 2025

Ekso Bionics Holdings, Inc Announces Director Changes

Ekso Bionics Holdings, Inc. acquired Human Motion and Control Business Unit of Parker Hannifin Corporation for $10 million.

Price target decreased to US$9.00

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Ekso Bionics Holdings, Inc. Approves Appointment of Jerome Wong as Corporate Secretary and Principal Financial Officer

Ekso Bionics Holdings, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Ekso Bionics: Fragile Opportunity

Second quarter 2022 earnings: EPS exceeds analyst expectations

Ekso Bionics Holdings, Inc. to Report Q2, 2022 Results on Jul 28, 2022

Is Ekso Bionics Holdings (NASDAQ:EKSO) A Risky Investment?

Ekso Bionics Holdings, Inc. Receives FDA Clearance to Market Its Eksonr(Tm) Robotic Exoskeleton for Use with Multiple Sclerosis Patients

Ekso Bionics Holdings, Inc. Announces Chief Financial Officer Changes

Ekso Bionics Holdings, Inc., Annual General Meeting, Jun 09, 2022

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$11.00

Ekso Bionics Holdings, Inc. to Report Q1, 2022 Results on Apr 28, 2022

Consensus forecasts updated